DCGI has approved first and second stage human clinical trials.
MRNA-based vaccines are indeed scientifically an ideal option.
New Delhi. India’s first corona vaccine based on native mRNA technology has been approved by the Drug Controller General of India (DCGI) for first and second stage human clinical trials. The Ministry of Earth Sciences gave this information on Friday. The HGCO-19 vaccine is under development by Genoa Biopharmaceuticals in Pune and is the first vaccine in India with mRNA technology, Kovid-19, which has been approved for first and second stage human trials. It has also received a grant within the framework of the IND-CEPI mission from the Department of Biotechnology, Ministry of Science and Technology.
This vaccine does not use traditional models to produce an immune response. The mRNA technique provides genetic instructions to human cells using the vaccine, so that they can develop proteins to fight the virus. In other words, the vaccine made by this technique makes such proteins in the cells of the body, which can mimic the proteins of the virus. This activates the immune system in case of infection and helps destroy the virus.
MRNA-based vaccines are indeed scientifically an ideal option, which is useful in the fight against rapid epidemics. The mRNA vaccine is considered safe. In addition, mRNA vaccines are completely synthetic. Genova manufactures this vaccine in collaboration with the American company HDT Biotech Corporation. HGCO-19 has previously demonstrated protective, immunity and neutralizing antibody activity in animals.